Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Pardes Biosciences, Inc. PRDS NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
26/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Pardes Biosciences, Inc. (PRDS) — Analyst outlook / Analyst consensus target is. Based on 3 analyst ratings, the consensus is bullish — 1 Buy, 2 Hold.

PRDS Analyst Ratings

Hold
3
Ratings
1 Buy
2 Hold
Based on 3 analysts giving stock ratings to Pardes Biosciences, Inc. in the past 3 months
Rating breakdown
Buy
1 33%
Hold
2 67%
33%
Buy
1 analysts
67%
Hold
2 analysts
0%
Sell
0 analysts

People Also View

NUVB
NUVB
Nuvation Bio Inc.
$4.85
+3.19%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.54
+3.42%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.44
+0.68%
 OVID
OVID
Ovid Therapeutics Inc.
$2.96
+6.09%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 STTK
STTK
Shattuck Labs, Inc.
$6.78
+0.15%
 IPSC
IPSC
Century Therapeutics, Inc.
$2.37
+4.41%
 CNTB
CNTB
Connect Biopharma Holdings Limited
$3.05
+7.77%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message